Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double‐blind, placebo‐controlled trial
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objectives: Recent research has focused on the inflammatory cascade as a key culprit in the etiology of bipolar disorder. We hypothesized that celecoxib, via its anti‐inflammatory properties, may have a therapeutic role in mood disorder. Methods: Forty‐six inpatients with the diagnosis of acute bipolar mania without psychotic features participated in a parallel, randomized, double‐blind, placebo‐controlled trial, and underwent six weeks of treatment with either celecoxib (400 mg daily) or placebo as an adjunctive treatment to sodium valproate. Patients were evaluated using the Young Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS). The primary outcome measure with respect to efficacy was the mean decrease in YMRS score from baseline to the study endpoint, which was compared between the two groups. Results: A significant difference was observed in the change in YMRS scores on Day 42 compared to baseline in the two groups (p < 0.001). The changes at the endpoint compared to baseline were −29.78 ± 21.78 (mean ± standard deviation) and −21.78 ± 7.16 for the celecoxib and placebo groups, respectively. A significantly higher remission rate was observed in the celecoxib group (87.0%) than the placebo group (43.5%) at Week 6 (p = 0.005). General linear model repeated measures demonstrated a significant effect for the time × treatment interaction on the YMRS scores [F(2.27,99.98) = 6.67, p = 0.001]. Conclusions: Celecoxib is an effective adjuvant therapy in the treatment of manic episodes (without psychotic features) of bipolar mood disorder. The mood‐stabilizing role of the drug might be mediated via its action on the inflammatory cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Basselin, M., Kim, H.-W., Chen, M., Ma, K., Rapoport, S. I., Murphy, R. C., & Farias, S. E. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002469 · Cited by 52
RetractedA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“The YMRS is an 11-item clinician-rated scale designed to evaluate the severity of manic symptoms (18).”
BackgroundA Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Kessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1561 · Cited by 868 · cited 2×
“Mood disorder is a major cause of disability worldwide (1).”
BackgroundMethodKessler, R. C., Akiskal, H. S., Ames, M., Birnbaum, H., Greenberg, P., .A, R. M., Jin, R., Merikangas, K. R., Simon, G. E., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1561 · Cited by 868
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Inflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609 · cited 1×
“Previous investigations provided support for a role for inflammatory mediators in modulating mood disorders (25).”
ResultComparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder
Brietzke, E., Stertz, L., Fernandes, B. S., Kauer-Sant’Anna, M., Mascarenhas, M., Escosteguy Vargas, A., Chies, J. A., & Kapczinski, F. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.12.001 · Cited by 423
Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder
Kim, Y.-K., Jung, H.-G., Myint, A.-M., Kim, H., & Park, S.-H. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.02.018 · Cited by 375
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.
O'Brien, S. M., Scully, P., Scott, L. V., & Dinan, T. G. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.11.015 · Cited by 285
Cytokine production in bipolar affective disorder patients under lithium treatment
Boufidou, F., Nikolaou, C., Alevizos, B., Liappas, I. A., & Christodoulou, G. N. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.01.007 · Cited by 130 · cited 1×
“Lithium, a popular mood stabilizer, reduces IL-2, IL-6, IL-10, and interferon (IFN) d levels after long-term use (7).”
BackgroundKhodaie-Ardakani, M.-R., Mirshafiee, O., Farokhnia, M., Tajdini, M., Hosseini, S.-M.-R., Modabbernia, A., Rezaei, F., Salehi, B., Yekehtaz, H., Ashrafi, M., et al. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.051 · Cited by 104
Self-citationFields, C., Drye, L., Vaidya, V., & Lyketsos, C. (2012) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318227f4da · Cited by 96
Research works printed but not linked: 31
- 10.1016/S0165-0327(98)00142-6 · DOI · Paper page
- 10.1016/S0140-6736(05)61500-0 · DOI
- 10.1586/ern.12.98 · DOI · Paper page
- 10.1016/S0006-3223(02)01452-X · DOI
- 10.1001/archpsyc.59.7.592 · DOI · Paper page
- 10.1016/j.plefa.2007.10.018 · DOI
- 10.1007/s00228-007-0400-7 · DOI · Paper page
- 10.1002/da.20589 · DOI · Paper page
- 10.1016/j.jad.2011.05.047 · DOI
- 10.1016/j.jad.2012.03.033 · DOI · Paper page
- 10.1186/1742-2094-5-17 · DOI · Paper page
- 10.1007/s11011-012-9326-6 · DOI
- 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- 10.1016/j.jad.2010.08.015 · DOI
- 10.1111/j.1399-5618.2006.00363.x · DOI · Paper page
- 10.1016/j.jad.2013.11.003 · DOI
- 10.1016/j.jpsychires.2014.08.016 · DOI
- Abbas AK, 2012, Cellular and Molecular Immunology
- 10.1111/j.1399-5618.2007.00493.x · DOI · Paper page
- 10.1016/j.jad.2011.08.022 · DOI
- 10.1016/S0165-0327(00)00252-4 · DOI
- 10.1007/s00406-007-0797-0 · DOI
- 10.1124/pr.111.005512 · DOI · Paper page
- 10.1111/j.1399-5618.2007.00444.x · DOI · Paper page
- Kargar M, 2014, Effects of celecoxib on inflammatory markers in bipolar patients undergoing electroconvulsive therapy: a placebo‐controlled, double‐blind, randomised study, Swiss Med Wkly, 144, w13880
- 10.1093/rheumatology/kep225 · DOI · Paper page
- 10.1016/j.schres.2006.11.016 · DOI · Paper page
- 10.1093/jnen/63.9.901 · DOI · Paper page
- 10.1016/j.schres.2010.04.015 · DOI · Paper page
- 10.1007/s00406-004-0478-1 · DOI
- 10.1016/j.biopsych.2005.02.024 · DOI
Cited by
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Revisiting inflammation in bipolar disorder
Fries, G. R., Walss-Bass, C., Bauer, M. E., & Teixeira, A. L. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.006 · Cited by 147
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Frankovich, J., Swedo, S., Murphy, T., Dale, R. C., Agalliu, D., Williams, K., Daines, M., Hornig, M., Chugani, H., Sanger, T., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0148 · Cited by 139
“Clinical trials have also shown benefit of NSAIDs in schizophrenia, bipolar disorder, and depression (Müller et al. 2004; Abbasi et al. 2012; Arabzadeh et al. 2015).”
Background
Metadata
- Authors
- Arabzadeh, S., Ameli, N., Zeinoddini, A., Rezaei, F., Farokhnia, M., Mohammadinejad, P., Ghaleiha, A., & Akhondzadeh, S.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2015-08-20
- Volume
- 17
- Issue
- 6
- Pages
- 606-614
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W2127819913
- Cited by
- 98
- References
- 14
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Tehran University of Medical Sciences (22216)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.